DKT. 30436.11US06/SBA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Peter S. Linsley et al.

Serial No

09/666,267

Filed

September 21, 2000

For

LIGAND FOR CD28 RECEPTOR ON B CELLS AND

METHODS

55 S. Lake Avenue, Suite 710
Pasadena, California 91101
September 23, 2002

Assistant Commissioner for Patents Box Sequence Arlington, VA 22202

SIR:

DECLARATION PURSUANT TO 37 C.F.R. §1.821(f)

I hereby declare that the content of the paper and computer readable copies of the Sequence Listings, submitted in the subject patent application in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same. The sequence listing contains no new matter pursuant to 37 C.F.R. 1.821(c), 1.821(f), 1.821(g), 1.825(b), or 1.825(d), and is supported by the specification as originally filed.

Respectfully submitted,

Renato Marco P. Domingo

30435.11US06/SBA/TYL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Peter S. Linsley et al.

Serial No.

09/666,267

Examiner: P. Gambel

Filed

September 21, 2000

Group Art Unit: 1644

For

LIGAND FOR CD28 RECEPTOR ON B CELLS AND METHODS

55 S. Lake Avenue, Suite 710 Pasadena, California 91101

Assistant Commissioner for Patents Washington, D.C. 20231

SIR:

UNDER MPEP § 608.01(p)

I hereby declare that the amendatory material submitted herewith, which is the predicted amino acid sequence of amino acids 1-216 of human B7 as published on page 2717 by Freeman, G.J. et al. in "B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic Cells", J. of Immunology, 143(8), 2714-2722, 1989, consists of the same material incorporated by reference in the above-referenced application (U.S. Serial No. 09/666,267).

Registration No. 51,946